Allergen immunotherapy in house dust mite-associated allergic rhinitis: efficacy of the 300 IR mite tablet

被引：0

作者：

Klimek L. ^{[1
]}

Brehler R. ^{[2
]}

Casper I. ^{[1
]}

Klimek F. ^{[1
]}

Hagemann J. ^{[3
]}

Cuevas M. ^{[4
]}

Bergmann K.-C. ^{[5
,6
]}

机构：

[1] Center for Rhinology and Allergology, Wiesbaden

[2] Clinic for Skin Diseases, Münster University Hospital, Muenster

[3] Department of Otorhinolaryngology, Mainz University Medical Center, Mainz

[4] Clinic and Polyclinic for Otorhinolaryngology, Carl Gustav Carus University Hospital, TU Dresden, Dresden

[5] Institute for Allergy Research, Charité—Universitätsmedizin Berlin, Berlin

[6] Allergology and Immunology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin

来源：

Allergo Journal International | 2023年 / 32卷 / 1期

关键词：

Allergen immunotherapy; Allergic asthma; Allergic rhinitis; House mites; Mite tablet;

D O I：

10.1007/s40629-022-00241-6

中图分类号：

学科分类号：

摘要：

Background: A perennial house dust mite-associated allergic rhinitis has a major impact on the quality of life of patients and is associated with a high socioeconomic burden. The most common symptoms of allergic rhinitis include a runny nose and nasal congestion, sneezing, itching of nose, mouth and/or throat, and/or ocular symptoms. Affected patients often develop allergic bronchial asthma. Therapy options for allergic rhinitis include allergen avoidance, symptomatic treatment, and allergen immunotherapy. Allergen immunotherapy is the only disease-modifying treatment that can permanently alleviate the symptoms of allergic rhinitis. In July 2021, a new sublingual mite tablet was approved in Germany. Methods: This review summarizes clinical studies on the 300 IR (index of reactivity) mite tablet in adolescents and adults with house dust mite-associated allergic rhinitis and presents the results. Results: In the phase II and phase III studies considered here, different dosages of the mite tablet were investigated. The 300 IR mite tablet showed the best benefit–risk profile and has been approved in Europe, Japan, South Korea, Australia, and New Zealand for the treatment of house dust mite-associated allergic rhinitis. Conclusion: Allergen immunotherapy with the 300 IR mite tablet is an effective treatment that relieves allergic symptoms, reduces the need for symptomatic medication, and improves the quality of life in both adults and adolescents with house dust mite-associated allergic rhinitis. At the same time, treatment with the 300 IR mite tablet is well tolerated. Mild to moderate reactions at the application site subside after a few days. © 2023, The Author(s).

引用

页码：10 / 17

页数：7

共 45 条

[11]

Shaaban R., Zureik M., Soussan D., Neukirch C., Heinrich J., Sunyer J., Et al., Rhinitis and onset of asthma: a longitudinal population-based study, Lancet, 372, pp. 1049-1057, (2008)

[12]

Klimek L., Bergmann K.-C., Casper I., Klimek F., Hagemann J., Cuevas M., Karenzmaßnahmen bei Milbenallergie – ein Update, Allergo J Int, (2022)

[13]

Calderon M.A., Kleine-Tebbe J., Linneberg A., De Blay F., Hernandez Fernandez de Rojas D., Virchow J.C., Et al., House dust mite respiratory allergy: an overview of current therapeutic strategies, J Allergy Clin Immunol Pract, 3, pp. 843-855, (2015)

[14]

Burks A.W., Calderon M.A., Casale T., Cox L., Demoly P., Jutel M., Et al., Update on allergy immunotherapy: American academy of allergy, asthma & immunology/European academy of allergy and clinical immunology/PRACTALL consensus report, J Allergy Clin Immunol, 131, pp. 1288-1296.e3, (2013)

[15]

Canonica G.W., Cox L., Pawankar R., Baena-Cagnani C.E., Blaiss M., Bonini S., Et al., Sublingual immunotherapy: World Allergy Organization position paper 2013 update, World Allergy Organ J, 7, (2014)

[16]

Orylmyte-Fachinformation, (2021)

[17]

Batard T., Hrabina A., Bi X.Z., Chabre H., Lemoine P., Couret M.-N., Et al., Production and proteomic characterization of pharmaceutical-grade Dermatophagoides pteronyssinus and Dermatophagoides farinae extracts for allergy vaccines, Int Arch Allergy Immunol, 140, pp. 295-305, (2006)

[18]

Demoly P., Corren J., Creticos P., De Blay F., Gevaert P., Hellings P., Et al., A 300 IR sublingual tablet is an effective, safe treatment for house dust mite-induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trial, J Allergy Clin Immunol, 147, pp. 1020-1030.e10, (2021)

[19]

Baron-Bodo V., Batard T., Nguyen H., Frereux M., Horiot S., Harwanegg C., Et al., Absence of IgE neosensitization in house dust mite allergic patients following sublingual immunotherapy, Clin Exp Allergy, 42, pp. 1510-1518, (2012)

[20]

Potapova E., Bordas-Le Floch V., Schlederer T., Vrtala S., Huang H.-J., Canonica G.W., Et al., Molecular reactivity profiling upon immunotherapy with a 300 IR sublingual house dust mite tablet reveals marked humoral changes towards major allergens, Allergy, 77, pp. 3084-3095, (2022)

← 1 2 3 4 5 →